Ki-67 Expression in Breast Cancer Tissue Microarrays

Academic Article

Abstract

  • © 2017 American Society for Clinical Pathology. All rights reserved. Objectives Ki-67 has been proposed to be used as a surrogate marker to differentiate luminal breast carcinomas (BCs). The purpose of this study was to determine the utility of and best approaches for using tissue microarrays (TMAs) and Ki-67 staining to distinguish luminal subtypes in large epidemiology studies of luminal/human epidermal growth factor receptor 2 (HER2)-negative BC. Methods Full-section and TMA (three 0.6-mm cores and two 1.0-mm cores) slides of 109 cases were stained with Ki-67 antibody. We assessed two ways of collapsing TMA cores: a weighted approach and mitotically active approach. Results For cases with at least a single 0.6-mm TMA core (n = 107), 16% were misclassified using a mitotically active approach and 11% using a weighted approach. For cases with at least a single 1.0-mm TMA core (n = 101), 5% were misclassified using either approach. For the 0.6-mm core group, there were 33.3% discordant cases. The number of discordant cases increased from 18% in the group of two cores to 40% in the group of three cores (P =.039). Conclusions Ki-67 tumor heterogeneity was common in luminal/HER2- BC. Using a weighted approach was better than using a mitotically active approach for core to case collapsing. At least a single 1.0-mm core or three 0.6-mm cores are required when designing a study using TMA.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Khoury T; Zirpoli G; Cohen SM; Geradts J; Omilian A; Davis W; Bshara W; Miller R; Mathews MM; Troester M
  • Start Page

  • 108
  • End Page

  • 118
  • Volume

  • 148
  • Issue

  • 2